Science versus policy
This article was originally published in The Gray Sheet
Executive Summary
Bipartisan panel issues recommendations to federal agencies Aug. 5 to more clearly distinguish scientific questions from policy disputes in proposed regulations. The Science for Policy Project report also urges more stringent standards against relying on experts with potential conflicts of interest for advisory committees and overall greater transparency in committee selection. The report suggests that a single disclosure form (with some flexibility for special requests) should be developed for all federal advisory panels, drawing off of the current forms for FDA and the Environmental Protection Agency. The panel, supported by the Bipartisan Policy Center, was chaired by former New York Republican Congressman Sherwood Boehlert and former FDA Commissioner and Science magazine editor Donald Kennedy
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.